Aptorum Group Limited (APM)
| Market Cap | 7.36M +16.0% |
| Revenue (ttm) | n/a |
| Net Income | -1.36M |
| EPS | -0.19 |
| Shares Out | 8.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 884,111 |
| Open | 1.0400 |
| Previous Close | 1.1200 |
| Day's Range | 0.8349 - 1.0400 |
| 52-Week Range | 0.6500 - 4.4700 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 31, 2026 |
About APM
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pse... [Read more]
Financial Performance
Financial StatementsNews
Aptorum Group shareholders approve merger with DiamiR Biosciences
Aptorum Group (APM) announced that its shareholders voted to approve the proposed all-stock merger with DiamiR Biosciences at a meeting on June 9. DiamiR’s shareholders also approved the transaction o...
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today annou...
Aptorum Group, DiamiR announce publication of microRNA biomarker study
Aptorum Group (APM) and DiamiR announced the publication of a paper by Giliberto, et. al. titled “Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics. Th...
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedica...
Aptorum Group receives noncompliance notification from Nasdaq
Aptorum Group (APM) announced that it has received a notification from Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing…
Aptorum Group announces collab between DiamiR, Instant NanoBiosensors
Aptorum Group (APM), DiamiR Biosciences, and Instant NanoBiosensors announced a collaboration between DiamiR and INB to validate INB’s automated APOE testing platform for clinical use in DiamiR’s CLIA...
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease
NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical...
Aptorum Group files $75M mixed securities shelf
16:32 EST Aptorum Group (APM) files $75M mixed securities shelf
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and oth...
Aptorum Group files to sell 2.06M Class A ordinary shares for holders
The company will not receive any proceeds from the sale of shares of Class A Common Stock by the selling securityholders.
Aptorum Group announces up to $6M registered direct offering
Aptorum Group (APM) announced that it has entered into definitive agreements for the purchase and sale of 1M Class A ordinary shares at a purchase price of $2.00 per share…
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants
Aptorum Group appoints Laura Philips to board of directors
Aptorum Group (APM) announces the addition of Laura Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp. Dr. Philips is…
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical nee...
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedi...
Why Is Aptorum Stock (APM) Up 115% Today?
Aptorum stock rallied on Thursday after the company announced new blood testing approval in New York.
Aptorum Group, DiamiR announce New York state approval for APOE Genotyping test
DiamiR Biosciences and Aptorum Group (APM) announced that DiamiR received a Clinical Laboratory Evaluation Program, CLEP, Test Approval for its APOE Genotyping test from the New York State Department ...
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and oth...
Aptorum Group regains compliance with Nasdaq minimum bid price rule
Aptorum Group (APM) received formal written notification from The Nasdaq Stock Market confirming that the company has regained compliance with Nasdaq’s minimum bid price requirement. The regaining of ...
Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet ...
Aptorum Group Ltd trading resumes
09:10 EDT Aptorum Group (APM) Ltd trading resumes
Aptorum Group, DiamiR Biosciences entered definitive merger agreement
Aptorum Group (APM) and DiamiR Biosciences announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become...
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet ...
Aptorum Group Ltd trading halted, news pending
08:11 EDT Aptorum Group (APM) Ltd trading halted, news pending
Aptorum Group receives Nasdaq non-compliance notification
Aptorum Group (APM) Limited announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of…